BioStock: Strong Q3 performance for Alligator Bioscience

Alligator Bioscience has reported a productive quarter, showing significant advancements in its cancer therapeutics pipeline, particularly its lead asset mitazalimab, which received Orphan Designation in Europe. Moreover, the company reached another milestone in its partnership with Orion Corporation and strengthened its financial foundation through a successful warrant exercise. The stage is set for a promising final quarter of the year, with key data slated for release in early 2024. BioStock spoke with CEO Søren Bregenholt to learn more.

Read the interview with Søren Bregenholt at biostock.se:

Strong Q3 performance for Alligator Bioscience - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/